These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Author: Preisack MB, Karsch KR.
    Journal: Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S55-8; discussion S59-60. PubMed ID: 8180331.
    Abstract:
    Restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) remains a major problem limiting the clinical efficacy of the procedure. It has been shown that smooth muscle cell proliferation plays a major role in this accelerated atherosclerotic process. In vitro and in vivo experiments with a low molecular weight heparin, reviparin-sodium suggest a pronounced inhibitory effect of this compound on smooth muscle cell proliferation. To evaluate the safety of reviparin-sodium and the incidence of angiographic restenosis in humans a study with increasing dosages was conducted in 41 patients. Repeat coronary angiography was performed 3 months after angioplasty. Restenosis occurred in five of 37 evaluative patients (14%) with initially successful PTCA. No major bleeding complications were documented for any patient in this trial. Thus, in this limited series, administration of reviparin-sodium resulted in a low incidence of restenosis following PTCA without causing major bleeding complications. A randomized, double-blind, multicentre trial is being carried out to define the real impact of this compound for reduction of restenosis in patients who underwent successful balloon angioplasty.
    [Abstract] [Full Text] [Related] [New Search]